Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar-Apr;31(2):191-9.
doi: 10.1016/j.clindermatol.2012.08.006.

Immunomodulatory therapy for melanoma: ipilimumab and beyond

Margaret K Callahan  1 , Michael A Postow, Jedd D Wolchok
Affiliations
Review

Immunomodulatory therapy for melanoma: ipilimumab and beyond

Margaret K Callahan et al. Clin Dermatol. 2013 Mar-Apr.

Abstract

In 2011, the U.S. Food and Drug Administration approved the first new therapy for melanoma in more than a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on activated T cells. Blockade of this important immune checkpoint can lead to durable tumor regression, and phase III studies show an overall survival benefit for patients with advanced melanoma. During the clinical development of ipilimumab, several unique features of this immunotherapy were identified, including the remarkable durability of responses and a distinct side-effects profile. We review the preclinical and clinical development of CTLA-4-blocking antibodies and describe current practices using ipilimumab for the treatment of advanced melanoma. Unique clinical issues related to ipilimumab will be summarized. Lastly, we will briefly preview combination therapies that incorporate ipilimumab and new checkpoint-targeting antibodies currently in clinical development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pre-Clinical and Clinical Development of CTLA-4 blocking Antibodies.
Figure 2
Figure 2. Co-stimulatory and Co-inhibitory Molecules Regulate T cell Activation
A diversity of activating and inhibitory signals are integrated to modulate the process of T cell activation. CTLA-4 is one of many inhibitory checkpoint molecules that regulate T cell activation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. - PMC - PubMed
    1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169(950):1042–9. - PubMed
    1. Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol. 2002;2(6):439–46. - PubMed
    1. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165(2):302–19. - PMC - PubMed
    1. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975;53(1):27–42. - PubMed